12 June 2024 - Today, the FDA granted traditional approval to selpercatinib (Retevmo, Eli Lilly) for adult and paediatric patients 2 years of age and older with advanced or metastatic RET fusion positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate).

Selpercatinib received accelerated approval for this indication for patients 12 years of age and older in 2020.

Read FDA press release